Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine

British Journal of Pharmacology

Volumn 118, Issue 5, 1996, Pages 1317-1325

  Singh, L ^b   Oles, R J ^b   Field, M J ^b   Atwal, P ^b   Woodruff, G N ^b   Hunter, J C ^a,b  

^a ROCHE BIOSCIENCE   (United States)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Antinociception; Cholecystokinin; Conditioned place preference; Dependence; Formalin; Gastrointestinal; Tailflick; Tolerance

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; ANTINOCICEPTIVE AGENT; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; MORPHINE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; GASTROINTESTINAL MOTILITY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REINFORCEMENT; SUBCUTANEOUS DRUG ADMINISTRATION; TAIL FLICK TEST;

EID: 0030056472     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15539.x     Document Type: Article

References (51)

1. BARBAZ, B.S., HALL, N.R. & LIEBMAN, J.M. (1989). Antagonism of morphine analgesia by CCK-8-S does not extend to all assays nor all opiate analgesics. Peptides, 9, 1295-1300.
2. BEINFELD, M.C. & PALKOVITS, M. (1982). Distribution of cholecystokinin (CCK) in the rat lower brain stem nuclei. Brain Res., 238, 260-265.
3. BODEN, P.R., HIGGENBOTTOM, M., HILL, D.R., HORWELL, D.C., HUGHES, J., REES, D.C., ROBERTS, E., SINGH, L., SUMANCHAUHAN, N. & WOODRUFF, G.N. (1993). Cholecystokinin dipeptoid antagonists: design, synthesis and anxiolytic profile of some CCK-A and CCK-B selective and mixed CCK A/B antagonists. J. Med. Chem., 36, 552-565.
4. CARR, G.D., FIBIGER, H.C. & PHILLIPS, A.G. (1989). Conditioned place preference as a measure of drug reward. In The Neuropharmacological Basis of Reward, ed Liebman, J.M. & Cooper, S.J. pp. 264-319. Oxford: Oxford University Press.
5. 3H]L-365,260: A new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand. Mol. Pharmacol., 35, 803-808.
6. CHANG, R.S.L. & LOTTI, V.J. (1986). Biochemical and pharmacological characterization of an extremely potent and selective non-peptide cholecystokinin antagonist. Proc. Natl. Acatl. Sci. U.S.A., 83, 4923-4926.
7. CRAWLEY, J.N. (1992). Subtype selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviours in the rat mesolimbic pathway. J. Neurosci., 12, 3380-3391.
8. DOURISH, C.T., HAWLEY, D. & IVERSEN, S.D. (1988). Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. Eur. J. Pharmacol., 147, 469-472.
9. DOURISH, C.T., O'NEILL, M.F., COUGHLAN, J., KITCHENER, S.J., HAWLEY, D. & IVERSEN, S.D. (1990). The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur. J. Pharmacol., 176, 35-44.
10. FARIS, P.L., KOMISARUK, B.R., WATKINS, L.R. & MAYER, D.J. (1983). Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science. 219, 310-312.
11. FUJI, K., SENBA, E., FUJII, S., NOMURA, I., WU, J.-Y., VEDA, Y. & TOHYAMA, M. (1985). Distribution, ontogeny and projections of cholecystokinin-8, vasoactive intestinal polypeptide and gamma-aminohutyrate containing neurons in rat spinal cord: an immunohistochemiocal analysis. Neuroscience, 14, 881-894.
12. GALL, C., LAUTERBORN, J., BURKS, D. & SEROOGY, K. (1987). Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain. Brain Res., 403, 403-408.
13. HIGGINS, G.A., JOHARCHI, N., WANG, Y., CORRIGALL, W.A. & SELLERS, E.M. (1994). The CCK-A receptor antagonist devazepide does not modify opioid self-administration or drug discrimination: comparison with the dopamine antagonist haloperidol. Brain Res., 640, 246-254.
14. HIGGINS, G.A., NGUYEN, P. & SELLERS, E.M. (1992). Morphine place conditioning is differentially affected by CCK-A and CCK-B receptor antagonists. Brain Res., 572, 208-215.
15. HILL, D.R., CAMPBELL, N.J., SHAW, T.M & WOODRLFF, G.N. (1987a). Autoradiographical localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective non-peptide CCK antagonists. J. Neurosci., 7, 2967-2976.
16. 125I-cholecyslokinin in primate spinal cord are of the CCK-A subclass. Neurosci. Lett., 89, 133-139.
17. HILL, D.R. & WOODRUFF, G.N. (1990). Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260. Brain Res., 526, 276-283.
18. HILL, R.G., HUGHES, J. & PITTAWAY, K.M. (1987b). Antinociceptive action of cholecystokinin octapeptide (CCK 8) and related peptides in rats and mice: effects of naloxone and peptidase inhibitors. Neuropharmacol., 26, 289-300.
19. HOKFELT, T., REHFELD, J.F., SKIRBOLL, L.R., IVEMARK, B., GOLDSTEIN, M. & MARKEY, K. (1980). Evidence for coexistence of dopamine and CCK in meso-limbic neurones. Nature, 285, 476-478.
20. HUGHES, J., BODEN, P.R., COSTALL, B., DOMENEY, A., KELLEY, E., HORWELL, D.C., HUNTER, J.C., PINNOCK, R.D. & WOODRUFF, G.N. (1990). Development of a class of selective cholecystokinin type B receptor antagonists having a potent anxiolytic activity. Proc. Natl. Acad. Sci. U.S.A.. 87, 6728-6732.
21. B/gastrin receptor in guinea-pig cerebral cortex and gastric glands. Mol. Pharmacol., 43, 595-602.
22. INNIS, R.B. & SYNDER, S.H. (1980). Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl. Acad. Sci. U.S.A., 77, 6917-6921.
23. JACKSON, A., TATTERSALL, D., BENTLEY, G., RYCROFT, W., BOURSON, A., HARGREAVES, R., TRICKLEBANK, M. & IVERSEN, S.D. (1994). An investigation into the discriminative stimulus and reinforcing properties of the CCKB-receptor antagonists, L-365,260 in rats. Neuropeptides, 26, 343-353.
24. KELLSTEIN, D.E. & MAYER, D.J. (1991). Spinal co-administration of cholecystokinin antagonists with morphine prevents the development of opioid tolerance. Pain, 47, 221-229.
25. LAL, H. (1979). Interoceptive stimuli as tools of drug development. Drug Dev. Indust. Pharm., 5, 133-146.
26. LAVIGNE, G.J., MILLINGTON, W.R. & MUELLER, G.P. (1992). The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260 enhance morphine antinociception only in non-acclimated rats exposed to a novel environment. Neuropeptides, 21, 119-129.
27. LING, G.S.F., MACLEOD, J.M., LEE. S., LOCKHART, S.H. & PASTERNACK, G.W. (1984). Separation of morphine analgesia from physical dependence. Science, 226, 462-464.
28. MALDONADO, R., DERRIEN, M., NOBLE, F. & ROQUES, B.P. (1993). Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses. Neuroreport, 4, 947-950.
29. MARSHALL, F.H., BARNES, S., HUGHES, J., WOODRUFF, G.N. & HUNTER, J.C. (1991). Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. J. Neurochem., 56, 917-922.
30. MORAN, T.H., ROBINSON, P.H., GOLDRICH, M.S. & MCHUGH, P.R. (1986). Two brain cholecystokinin receptors: implications for behavioural actions. Brain Res., 362, 175-179.
31. NOBLE, F., DERRIEN, M. & ROQUES, B.P. (1993). Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br. J. Pharmacol., 109, 1064-1070.
32. PANERAI, A.E., ROVATI, L.C., COCCO, E., SACERDOTE, P. & MANTEGAZZA, P. (1987). Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin. Brain Res., 40, 52-60.
33. 8. Functional significance of subregional distributions. Neurochem. Int., 10, 495-508.
34. PHILLIPS, A.G., LE PAINE, F.G. & FIBIGER, H.C. (1984). Dopaminergic mediation of reward produced by direct injection of enkephalin into the ventral tegmental area of the rat. Life Sci., 33, 2505-2511.
35. PISEGNA, J.R., DE WEERTH, A., HUPPI, K & WANK, S.A. (1992). Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization. Biochem. Biophys. Res. Commun., 189, 296-303.
36. SINGH, L., FIELD, M.J., VASS, C.A., HUGHES, J. & WOODRUFF, G.N. (1992). The antagonism of benzodiazepine withdrawal effects by the selective cholecystokinin-B receptor antagonist CI-988. Br. J. Pharmucol., 105, 8-10.
37. SINGH, L., LEWIS, A.S., FIELD, M.J., HUGHES, J. & WOODRUFF, G.N. (1991). Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc. Natl. Acad. Sci. U.S.A., 88, 1130-1133.
38. SPYRAKI, C., FIBIGER, H.C. & PHILLIPS, A.G. (1983). Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system. Psychopharmacol., 79, 278-283.
39. STANFA, L.C. & DICKENSON, A. (1993). Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation. Br. J. Pharmacol., 108, 967-973.
40. STANFA, L.C., SULLIVAN, A.F. & DICKENSON, A.H. (1992). Alterations in neuronal excitability and the potency of spinal mu, delta and kappa opioids after carrageenan induced inflammation. Pain, 50, 345-354.
41. STENGAARD-PEDERSEN, K. & LARSSON, L.-I. (1981). Localization and opiate receptor binding of enkephalin, CCK and ACTH/ beta-endorphin in the rat central nervous system. Peptides, Suppl. 1, 3-19.
42. TRICKLEBANK, M.D., SINGH, L., OLES, R.J., PRESTON, C. & IVERSEN, S.D. (1989). The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur. J. Pharmacol., 167, 127-135.
43. VACCARINO, F.J. & KOOB, G.F. (1984). Microinjections of nanogram amounts of sulfated cholecystokinin octapeptide into the rat nucleus accumbens attenuates brain stimulation reward. Neurosci. Lett., 52, 61-66.
44. 3H]cholecystokinin as radioligand. J. Neurosci., 4, 1021-1033.
45. WANK, S.A., PISEGNA, J.R. & DE WEERTH, A. (1992). Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc. Natl. Acad. Sci. U.S.A., 89, 8691-8695.
46. WATKINS, L.R., KINSCHEK, I.B., KAUFMAN, E., MILLER. J., FRENK, H. & MAYER, D.J. (1985a). Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates. Brain Res., 327, 181-190.
47. WATKINS, L.R., KINSCHEK, I.B. & MAYER, D.J. (1985b). Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide. Brain Res., 327, 169-180.
48. WIESENFELD-HALLIN, Z., XU, X.-J., HUGHES, J., HORWELL, D.C. & HOKFELT, T. (1990). PD 134308, a selective antagonist of cholecystokinin type-B receptors, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc. Natl. Acad. Sci. U.S.A., 87, 7105-7109.
49. WHITE, N., PACKARD, M.G. & HIROI, N. (1991). Place conditioning with dopamine D1 and D2 agonists injected peripherally or into nucleus accumbens. Psychopharmacol., 103, 271-276.
50. WOODRUFF, G.N. & HUGHES, J. (1991). Cholecystokinin antagonists. Ann. Rev. Pharmacol. Toxicol., 31, 469-501.
51. ZETLER, G. (1984). Ceruletide, ceruletide analogues and cholecystokinin octapeptide (CCK-8): Effects on isolated intestinal preparations and gallbladders of guinea-pigs and mice. Peptides, 5, 729-736.